Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The company plans to add 1700 beds by FY27 through the organic route
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Pharma Solutions operates 10 research and development and/or production sites globally
Subscribe To Our Newsletter & Stay Updated
